(Date:5/12/2008)...ire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT) World H...") announced,that the Toronto Stock Exchange ("TSX...g the eligibility for continued listing on the TSX... 709 and 710(a) of the TSX Company,Manual. This re...and,operating results, more specifically whether t...
(Date:5/12/2008)...rstCall/ -- Allied Healthcare Products,Inc. (Nasd... the third,quarter ending March 31 fell 64 percent...are, to about $100,000 in the current quarter, or ...creased by about $240,000 compared to the,third qu...and labor costs,this fiscal year eroded margins an...
(Date:5/12/2008)...Newswire-FirstCall/ -- China Yingxia,International... or "the,Company"), a leading provider in the nutr...ufacture and distribution of organic nutritional f...cts in the People,s Republic,of China ("PRC"), ann...iday, May 16, 2008, at 10:00 a.m. EDT, to discuss ...
(Date:5/12/2008)...RME TSX: COM, VANCOUVER, May 12 /PRNewswire-First... COM) today announced that it will report financia...ernoon of Tuesday, May 13,2008. Cardiome will hol...ern (1:30pm Pacific) on that day to discuss the re...l 416-641-6117 or,866-299-6655. There will be a se...
Breaking Medicine News(10 mins):Health News:WorldHeart Notified of TSX Delisting Review 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4(Date:5/12/2008)... ATLANTA, May 12 /- Geo...nta- based HIV/AIDS vaccine development,company, a...ion common,stock purchase agreement with Fusion Ca...investor., The Company may sell up to $10 million...o time over a 25-month period after the Securities...
(Date:5/12/2008)... ANN ARBOR, Mich., May 12 /- Velc...mpletion of a first-in-man clinical trial for,its ...stigating as a,treatment for Rheumatoid Arthritis ...ical studies, VEL-0230 proved to be a powerful,ant...mation and inhibits,bone loss. Taken together, the...
(Date:5/12/2008)... Provides the Optimal Combination of Scaffoldi... Conformability, TEL AVIV, Israel, May 12 /PRNews...received CE Mark for its Presillion(TM) CoCr Coron...rtery lesions with a technologically,innovative fl...preserves the superb scaffolding the unprecedented...
(Date:5/12/2008)... Presentation of Phase 1 Clinical Data of MDX-1100... 2008, PRINCETON, N.J., May 12 /PRNewswi...nounced today that it has initiated the Phase 2 cl...man monoclonal antibody that,targets CXCL10 (also ...eumatoid arthritis (RA). MDX-1100 could potentiall...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy 2Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4What are the causes and consequences of childhood obesity 3F 1889 1Story ideas from the Journal of Biological Chemistry 1885 1Study examines decision making deficits in older adults 9510 1Study examines decision making deficits in older adults 9510 2Study examines decision making deficits in older adults 9510 3Edwards Lifesciences Completes Sale of LifeStent Product Line to Bard 9507 1... Mymetics Also Announces Deal for Vaccine Delivery...wire-FirstCall/ --,Mymetics Corporation announced ...mucosal antibodies in a non-human primate model.,M...rst line of,defense against infection by HIV. The ...tics, Chief Scientific Officer in an,oral presenta...
... SAN DIEGO, March 29, 2007 /PRNewswire-FirstCall/...ceutical research and,development company focuse...tes for the treatment of cancer and infectious dis...ical studies of ANX-510,(CoFactor(R)) in combina...capecitabine (Xeloda(R)), an oral prodrug of 5-FU,...
Other Medicine Technology:Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 2Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 4ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 2ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 3...new standard in the field of hammertoe implants wi...ical grade silicone, these durable and lasting imp... flexibility while maintaining correct toe length ...stiffnesses. Lengths are determined by the surgeon...
...Nerve Electrodes provide direct cranial nerve moni... circumferential design provides sensitive contact...l-time recordings. This unique approach provides y... acoustic neuromas, microvascular decompressions, ...
State-of-the-art sleep recording and analysis
... offers the capability to acquire images in near-r...ess and Contrast levels, Auto-windowing, Image Man...e tube's Rhodium spectrum which is best adapted to...on flat panel digital detector, which is the resul...
Medicine Products: